Bone mineral density and laboratory evaluation of a type II autosomal dominant osteopetrosis carrier

被引:0
作者
Takacs, I
Cooper, H
Weaver, DD
Econs, MJ
机构
[1] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA
来源
AMERICAN JOURNAL OF MEDICAL GENETICS | 1999年 / 85卷 / 01期
关键词
autosomal dominant osteopetrosis type II (ADO2); penetrance; carrier; creatine kinase isoenzyme BB (CK-BB);
D O I
10.1002/(SICI)1096-8628(19990702)85:1<9::AID-AJMG4>3.0.CO;2-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Type II autosomal dominant osteopetrosis (ADO2) is an inherited disorder characterized by increased skeletal mass and characteristic abnormalities evident on radiography, Although previous investigators have described nonpenetrant individuals (carriers), it is not known whether carriers manifest subtle abnormalities, We hypothesized that ADO2 carriers would have an abnormality of osteoclast function that would lead to changes in bone mineral density (BRID), in serum tartrate-resistant acid phosphatase (TRAP), or in creatine kinase isoenzyme BE (CK-BB) levels that would permit carrier recognition. We identified a female carrier in a well-established ADO2 family and measured BMD, serum TRAP, and CK-BB concentrations. She had normal BMD, serum TRAP, and CK-BB concentrations. Thus, these measurements cannot be used to exclude carrier status in individuals who are seen for genetic counseling. However, measurements in other asymptotic carriers are necessary before concluding that these measurements are normal in all or most nonpenetrant individuals, Am. J. Med. Genet. 85:9-12, 1999. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:9 / 12
页数:4
相关论文
共 11 条
  • [1] Tartrate-resistant acid phosphate activity as osteoclastic marker: Sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry
    Ballanti, P
    Minisola, S
    Pacitti, MT
    Scarnecchia, L
    Rosso, R
    Mazzuoli, GF
    Bonucci, E
    [J]. OSTEOPOROSIS INTERNATIONAL, 1997, 7 (01) : 39 - 43
  • [2] BOLLERSLEV J, 1993, CLIN ORTHOP RELAT R, P45
  • [3] BOLLERSLEV J, 1987, CLIN GENET, V31, P86
  • [4] FRACTURE PATTERNS IN 2 TYPES OF AUTOSOMAL-DOMINANT OSTEOPETROSIS
    BOLLERSLEV, J
    ANDERSEN, PE
    [J]. ACTA ORTHOPAEDICA SCANDINAVICA, 1989, 60 (01): : 110 - 112
  • [5] BOLLERSLEV J, 1995, ENDOCRINE REV MONOGR, V4, P365
  • [6] Recent developments in the understanding of the pathophysiology of osteopetrosis
    Felix, R
    Hofstetter, W
    Cecchini, MG
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1996, 134 (02) : 143 - 156
  • [7] GRODUM E, 1995, BONE, V16, P431
  • [8] OSTEOPETROSIS - A CLINICAL GENETIC METABOLIC AND MORPHOLOGIC STUDY OF DOMINANTLY INHERITED BENIGN FORM
    JOHNSTON, CC
    LAVY, N
    LORD, T
    VELLIOS, F
    MERRITT, AD
    DEISS, WP
    [J]. MEDICINE, 1968, 47 (02) : 149 - +
  • [9] LAU KHW, 1987, CLIN CHEM, V33, P458
  • [10] Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders
    Whyte, MP
    Chines, A
    Silva, DP
    Landt, Y
    Ladenson, JH
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (10) : 1438 - 1443